KOPRAN
|
KOPRAN Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 10.57 | 5.65 | 12.66 | 14.24 | 4.86 |
| CEPS(Rs) | 13.24 | 8.29 | 14.96 | 16.60 | 7.07 |
| DPS(Rs) | 3.00 | 3.00 | 3.00 | 1.50 | - |
| Book NAV/Share(Rs) | 101.68 | 91.11 | 88.40 | 56.65 | 43.86 |
| Tax Rate(%) | 24.56 | 24.49 | 25.37 | 26.07 | 25.68 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 12.10 | 9.28 | 18.00 | 16.29 | 12.92 |
| EBIT Margin(%) | 12.39 | 7.55 | 17.93 | 17.87 | 10.29 |
| Pre Tax Margin(%) | 10.99 | 6.46 | 16.88 | 16.63 | 7.82 |
| PAT Margin (%) | 8.29 | 4.88 | 12.60 | 12.29 | 5.81 |
| Cash Profit Margin (%) | 10.39 | 7.16 | 14.89 | 14.33 | 8.46 |
| Performance Ratios | |||||
| ROA(%) | 7.32 | 4.32 | 11.62 | 15.22 | 5.84 |
| ROE(%) | 10.96 | 6.29 | 18.19 | 28.34 | 11.74 |
| ROCE(%) | 13.78 | 8.30 | 21.40 | 30.40 | 13.69 |
| Asset Turnover(x) | 0.88 | 0.89 | 0.92 | 1.24 | 1.00 |
| Sales/Fixed Asset(x) | 2.47 | 2.53 | 2.66 | 3.30 | 2.54 |
| Working Capital/Sales(x) | 2.61 | 2.51 | 1.84 | 4.31 | 4.38 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.40 | 0.39 | 0.38 | 0.30 | 0.39 |
| Receivable days | 111.32 | 94.82 | 93.20 | 77.53 | 90.59 |
| Inventory Days | 79.90 | 91.76 | 94.14 | 68.65 | 81.75 |
| Payable days | 97.72 | 81.67 | 108.83 | 90.60 | 100.26 |
| Valuation Parameters | |||||
| PER(x) | 24.45 | 19.55 | 22.24 | 7.37 | 5.22 |
| PCE(x) | 19.51 | 13.33 | 18.82 | 6.32 | 3.58 |
| Price/Book(x) | 2.54 | 1.21 | 3.19 | 1.85 | 0.58 |
| Yield(%) | 1.16 | 2.72 | 1.07 | 1.43 | - |
| EV/Net Sales(x) | 2.17 | 1.08 | 2.88 | 1.04 | 0.54 |
| EV/Core EBITDA(x) | 14.95 | 10.85 | 14.03 | 5.15 | 4.08 |
| EV/EBIT(x) | 17.48 | 14.12 | 15.82 | 5.73 | 5.19 |
| EV/CE(x) | 2.25 | 1.16 | 2.25 | 1.17 | 0.52 |
| M Cap / Sales | 2.03 | 0.97 | 2.84 | 0.92 | 0.30 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 11.54 | 15.38 | -2.91 | 36.81 | 0.45 |
| Core EBITDA Growth(%) | 62.27 | -44.02 | -1.77 | 110.80 | -4.18 |
| EBIT Growth(%) | 80.64 | -51.50 | -2.99 | 140.82 | -8.51 |
| PAT Growth(%) | 87.11 | -55.38 | -0.93 | 193.08 | -12.50 |
| EPS Growth(%) | 87.11 | -55.38 | -11.13 | 193.07 | -12.50 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.20 | 0.17 | 0.17 | 0.27 | 0.47 |
| Current Ratio(x) | 2.08 | 2.25 | 2.74 | 1.72 | 1.59 |
| Quick Ratio(x) | 1.44 | 1.52 | 1.75 | 1.10 | 0.96 |
| Interest Cover(x) | 8.86 | 6.93 | 16.98 | 14.36 | 4.17 |
| Total Debt/Mcap(x) | 0.08 | 0.14 | 0.05 | 0.15 | 0.81 |
Compare Financial Ratios of peers of KOPRAN
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| KOPRAN | ₹1,562.9 Cr | -6.5% | 4.1% | 46.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹443,025.0 Cr | -0.4% | 4.7% | 60.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹144,299.0 Cr | -1.1% | 11% | 43.2% | Stock Analytics | |
| CIPLA | ₹132,316.0 Cr | -1.3% | 2.8% | 33.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,579.0 Cr | -2.3% | -7.8% | 14.4% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹106,092.0 Cr | -5.7% | -12.6% | 68.7% | Stock Analytics | |
KOPRAN Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| KOPRAN | -6.5% |
4.1% |
46.3% |
| SENSEX | 0.3% |
3% |
23.3% |
You may also like the below Video Courses
